Matches in SemOpenAlex for { <https://semopenalex.org/work/W1649840710> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W1649840710 endingPage "82" @default.
- W1649840710 startingPage "475" @default.
- W1649840710 abstract "Despite the important advances observed in the last 25 years in the comprehension of the clinical and biological nature of breast cancer and its treatment, this disease remains a significant cause of cancer morbidity and mortality worldwide. The clinical trial Hera has demonstrated the safety and efficacy of trastuzumab in the treatment of HER2 positive (HER2+) breast cancer patients, in early stages, subsequent to surgery, chemotherapy (neoadjuvante or adjuvant) and radiotherapy, if applied.To evaluate the cost-effectiveness of 1-year trastuzumab treatment versus standard care (observation following standard adjuvant chemotherapy), in patients with HER2+ breast cancer in early stages from the societal and the Portuguese National Health Service (NHS) perspectives.A 5-state Markov model with annual transition cycles was developed to estimate the long term health and economic outcomes of HER2+ early breast cáncer patients based on HERA clinical trial results. Portuguese NHS resource use and costs were estimated from a consensus expert panel and published unit costs, respectively. Clinical and economic outcomes were discounted at 3% per annum. The incremental cost-effectiveness ratios per life year gained (LYG) and per quality adjusted life year (QALY) gained were estimated. One-way sensitivity analysis was performed.Considering a 45 year time horizon, treatment with trastuzumab was estimated to increase discounted life expectancy by 2,114 life years and quality-adjusted life expectancy by 2,009 QALYs compared to standard care. Direct and indirect costs were projected to be 61.839 euro and 19.759 euro with trastuzumab and 40.559 euro and 25.392 euro with standard of care. These results corresponded to incremental cost-effectiveness ratios of 10.067 euro and 10.595 euro assuming direct costs only, and of 7.400 euro and 7.789 euro including indirect costs, per life year gained and per QALY gained, respectively.The 1-year trastuzumab use as adjuvant therapy in HER-2+ early breast cancer patients improves survival and can be considered a cost effective therapy with a high degree of certainty in the Portuguese setting." @default.
- W1649840710 created "2016-06-24" @default.
- W1649840710 creator A5007981572 @default.
- W1649840710 creator A5017700527 @default.
- W1649840710 creator A5036172775 @default.
- W1649840710 creator A5062936667 @default.
- W1649840710 creator A5081514352 @default.
- W1649840710 date "2010-07-27" @default.
- W1649840710 modified "2023-09-24" @default.
- W1649840710 title "[Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal]." @default.
- W1649840710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20654267" @default.
- W1649840710 hasPublicationYear "2010" @default.
- W1649840710 type Work @default.
- W1649840710 sameAs 1649840710 @default.
- W1649840710 citedByCount "4" @default.
- W1649840710 countsByYear W16498407102012 @default.
- W1649840710 countsByYear W16498407102013 @default.
- W1649840710 countsByYear W16498407102019 @default.
- W1649840710 countsByYear W16498407102022 @default.
- W1649840710 crossrefType "journal-article" @default.
- W1649840710 hasAuthorship W1649840710A5007981572 @default.
- W1649840710 hasAuthorship W1649840710A5017700527 @default.
- W1649840710 hasAuthorship W1649840710A5036172775 @default.
- W1649840710 hasAuthorship W1649840710A5062936667 @default.
- W1649840710 hasAuthorship W1649840710A5081514352 @default.
- W1649840710 hasConcept C112930515 @default.
- W1649840710 hasConcept C121608353 @default.
- W1649840710 hasConcept C126322002 @default.
- W1649840710 hasConcept C133925201 @default.
- W1649840710 hasConcept C143998085 @default.
- W1649840710 hasConcept C159110408 @default.
- W1649840710 hasConcept C160735492 @default.
- W1649840710 hasConcept C162324750 @default.
- W1649840710 hasConcept C177713679 @default.
- W1649840710 hasConcept C2779786085 @default.
- W1649840710 hasConcept C2779951463 @default.
- W1649840710 hasConcept C2908647359 @default.
- W1649840710 hasConcept C3019080777 @default.
- W1649840710 hasConcept C50522688 @default.
- W1649840710 hasConcept C530470458 @default.
- W1649840710 hasConcept C535046627 @default.
- W1649840710 hasConcept C64332521 @default.
- W1649840710 hasConcept C71924100 @default.
- W1649840710 hasConcept C99454951 @default.
- W1649840710 hasConceptScore W1649840710C112930515 @default.
- W1649840710 hasConceptScore W1649840710C121608353 @default.
- W1649840710 hasConceptScore W1649840710C126322002 @default.
- W1649840710 hasConceptScore W1649840710C133925201 @default.
- W1649840710 hasConceptScore W1649840710C143998085 @default.
- W1649840710 hasConceptScore W1649840710C159110408 @default.
- W1649840710 hasConceptScore W1649840710C160735492 @default.
- W1649840710 hasConceptScore W1649840710C162324750 @default.
- W1649840710 hasConceptScore W1649840710C177713679 @default.
- W1649840710 hasConceptScore W1649840710C2779786085 @default.
- W1649840710 hasConceptScore W1649840710C2779951463 @default.
- W1649840710 hasConceptScore W1649840710C2908647359 @default.
- W1649840710 hasConceptScore W1649840710C3019080777 @default.
- W1649840710 hasConceptScore W1649840710C50522688 @default.
- W1649840710 hasConceptScore W1649840710C530470458 @default.
- W1649840710 hasConceptScore W1649840710C535046627 @default.
- W1649840710 hasConceptScore W1649840710C64332521 @default.
- W1649840710 hasConceptScore W1649840710C71924100 @default.
- W1649840710 hasConceptScore W1649840710C99454951 @default.
- W1649840710 hasIssue "3" @default.
- W1649840710 hasLocation W16498407101 @default.
- W1649840710 hasOpenAccess W1649840710 @default.
- W1649840710 hasPrimaryLocation W16498407101 @default.
- W1649840710 hasRelatedWork W1513777602 @default.
- W1649840710 hasRelatedWork W1967814517 @default.
- W1649840710 hasRelatedWork W1983463961 @default.
- W1649840710 hasRelatedWork W2013424358 @default.
- W1649840710 hasRelatedWork W2019707316 @default.
- W1649840710 hasRelatedWork W2058901727 @default.
- W1649840710 hasRelatedWork W2067773355 @default.
- W1649840710 hasRelatedWork W2084572083 @default.
- W1649840710 hasRelatedWork W2098775844 @default.
- W1649840710 hasRelatedWork W2100717480 @default.
- W1649840710 hasRelatedWork W2101998240 @default.
- W1649840710 hasRelatedWork W2194721905 @default.
- W1649840710 hasRelatedWork W2743656444 @default.
- W1649840710 hasRelatedWork W2792730555 @default.
- W1649840710 hasRelatedWork W2901231398 @default.
- W1649840710 hasRelatedWork W2921099093 @default.
- W1649840710 hasRelatedWork W2990859622 @default.
- W1649840710 hasRelatedWork W3036094102 @default.
- W1649840710 hasRelatedWork W3132962672 @default.
- W1649840710 hasRelatedWork W3184904030 @default.
- W1649840710 hasVolume "23" @default.
- W1649840710 isParatext "false" @default.
- W1649840710 isRetracted "false" @default.
- W1649840710 magId "1649840710" @default.
- W1649840710 workType "article" @default.